Replies to post #358 on Equity Field Notes from temporal sources

[DanWebzster]

MTEM is an early stage clinical oncology biotech with some gravitas in the form of important partnerships with AFMD & Takeda.

The lead program is in a Ph1-b study in non-Hodgkins Lymphoma (NHL). Some extension 1-b results are due 12/18. The Ph1-a results were presented at ASCO and were uninspiring.

MTEM has a research collaboration with AFMD to identify antibodies for MTEM's targets using the ABsieve tool.

Perhaps this approach lead to the recently announced partnership with Takeda. This partnership came with a $30mn upfront payment.

With this upfront payment, MTEM has an operational runway thru 2020.

I will not be interested in the stock until after Ph1-b NHL results are announced.